• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Vaccines, Blood & Biologics

  • Print
  • Share
  • E-mail

BK070066 Letter

December 13, 2007

Gambro BCT, Inc.
Attention: Mr. Prabodh Gupta
10811 W. Collins Ave.
Lakewood , CO 80215-4498

Re: BK070066
Product: Vista Information System, Version 3.0 with Medical Review Module
Date Received: 15-NOV-07
Classification: II
Device Code: MMH

Dear Mr. Gupta:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device has been classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice on promotional labeling and advertisement for your device, please contact our Advertising and Promotional Labeling Staff (HFM-602) at (301) 827-3028. Also, please note the regulation entitled, ² Misbranding by reference to premarket notification ² (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number ( 800) 835-4709 or (301) 827-1800 or at its Internet address: http://www.fda.gov/cber/smlbus.htm .

Sincerely yours,

-- signature --

Basil Golding, M.D.
Director
Division of Hematology
Office of Blood Research and Review
Center for Biologics Evaluation and Research

Enclosure


 

Indications for Use

510(k) Number: BK070066
Device Name: Vista Information System, Version 3.0 with Medical Review Module

Indications For Use:

  • Provide capability for the operator to identify current and new donors.
  • Collection of data from apheresis procedures performed on Gambro BCT Trima Systems.
  • Provide manual capability for the operator to enter procedure data for procedures performed on Gambro BCT Spectra Systems and non-Gambro BCT Systems including whole blood collections.
  • Support for 21 CFR Part I I-compliance (Electronic Record/ Signature).
  • Maintain a complete record of blood component donation including supplies used.
  • Support for managing whole blood donation including use of Copper Sulphate tests.
  • Integrate with the Blood Bank System software to reduce duplicate data entry and to insure accuracy of data used in both the system. Operates cooperatively with Blood Bank System. Obtain donor data from the Blood Bank System and upload procedure information in the Blood Bank System.
  • Allow the blood center to determine donor eligibility to donate specific blood components (platelets, plasma and red blood cells). The eligibility will include frequency and interval period limits. Assist the operator in scheduling of donors by determining the next eligible date for each blood component.
  • Set up the Trima System with Configuration and donor data.